MicroRNAs as Bile-Based Biomarkers in Pancreatic Cancer and Biliary Tract Cancers
Poster May 09, 2017
M. Mato Prado*1, A. E. Frampton*1,2, N. Funel3,4, E. Lopez-Jimenez1, L. Castellano1, P. Lawton1, L. L. Meijer5, G. Kazemier5, L. R. Jiao2, J. Stebbing*1, E. Giovannetti*4,6, J. Krell*1
Pancreatic cancer is one of the most lethal diseases in the world with 9,618 new cases and around 8,800 deaths in the UK. It is the fourth most common cause of cancer death in the UK (2014). The lack of efficient diagnostic techniques and limited treatment options leads to a late detection and poor survival rates (less than 1%)1.Therefore, further investigation is needed to improve the detection process and design specific molecular targeted treatments.
During last decade, a class of non-coding RNAs (microRNAs) are emerging as potential biomarkers and therapeutic targets for different cancers. In this study, the role of miRNAs has been assessed in a large cohort of pancreatic cancer.
Is Oxford Nanopore Technology Ready for Clinical Diagnostics?Poster
Our objective is to validate diagnostic services using Oxford Nanopore’s Minion in the first instance and to evaluate the cost and performance compared to existing sequencing technology in areas such as tumour DNA sequencing (and circulating tumour DNA), virology, microbiology, genetics and HLA-typing.READ MORE
Performance of the D5000 and High Sensitivity D5000 ScreenTape Assays for the 4200 TapeStation SystemPoster
Here, we focus on quantification, sizing, and sensitivity of both D5000 ScreenTape assays.READ MORE
Comments | 0 ADD COMMENT
2nd Partnership in Biocontrol, Biostimulants & Microbiome Congress
Nov 02 - Nov 03, 2017
EMBL Course: Analysis of Non-Coding RNAs: quaerite et invenietis
Sep 09 - Sep 15, 2017